ArticleBioengineering & translational medicine2019
Lipid nanoparticles silence tumor necrosis factor α to improve wound healing in diabetic mice.
Article in Bioengineering & translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- The effect of low-level laser therapy on diabetic foot ulcers: A meta-analysis of randomised controlled trials.International wound journal · 2021Pooled it
- Enhanced Epigenetic Modulation via mRNA-Encapsulated Lipid Nanoparticles Enables Targeted Anti-inflammatory Control.ACS synthetic biology · 2026Article
- The Role of Gene Therapy and RNA-Based Therapeutic Strategies in Diabetes.International journal of molecular sciences · 2025Review
- The development of a direct co-culture-based model for diabetic foot ulcer mimicking inflammation and impaired phagocytosis.In vitro models · 2025Article
- Multifunctional Carbon-Based Nanocomposite Hydrogels for Wound Healing and Health Management.Gels (Basel, Switzerland) · 2025Review
- Functional nucleic acids for the treatment of diabetic complications.Nanoscale advances · 2023Review
- The emerging potential of siRNA nanotherapeutics in treatment of arthritis.Asian journal of pharmaceutical sciences · 2023Review
- Transforming Wound Management: Nanomaterials and Their Clinical Impact.Pharmaceutics · 2023Review
- Skin Inflammation with a Focus on Wound Healing.Advances in wound care · 2023Review
- Tongxinluo promotes endothelium-dependent arteriogenesis to attenuate diabetic peripheral arterial disease.World journal of diabetes · 2023Article
- Combinational System of Lipid-Based Nanocarriers and Biodegradable Polymers for Wound Healing: An Updated Review.Journal of functional biomaterials · 2023Review
- Microenvironment-Based Diabetic Foot Ulcer Nanomedicine.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Macrophages as a therapeutic target to promote diabetic wound healing.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Review
- Novel Pharmaceutical Strategies for Enhancing Skin Penetration of Biomacromolecules.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Nanobiotechnology: Applications in Chronic Wound Healing.International journal of nanomedicine · 2022Review
- Approaches to Modulate the Chronic Wound Environment Using Localized Nucleic Acid Delivery.Advances in wound care · 2021Review
- Limited Treatment Options for Diabetic Wounds: Barriers to Clinical Translation Despite Therapeutic Success in Murine Models.Advances in wound care · 2021Article
- Nanotechnology Approaches in Chronic Wound Healing.Advances in wound care · 2021Review
- Mesenchymal stem cell-inspired microgel scaffolds to control macrophage polarization.Bioengineering & translational medicine · 2021Article
- Low mortality oxidative stress murine chronic wound model.BMJ open diabetes research & care · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus is a mounting concern in the United States, as are the mortality and morbidity that result from its complications. Of particular concern, diabetes patients frequently suffer from impaired wound healing and resultant nonhealing diabetic foot ulcers. These ulcers overproduce tumor necrosis factor α (TNFα), which reduces wound bed cell migration and proliferation while encouraging apoptosis. Herein, we describe the use of siRNA-loaded lipid nanoparticles (LNPs) as a potential wound treatment to combat an overzealous immune response and facilitate wound closure. LNPs were formulated with an ionizable, degradable lipidoid and siRNA specific for TNFα. Topical application of nanoparticles reduced TNFα mRNA expression in the wound by 40-55% in diabetic and nondiabetic mice. In diabetic mice, this TNFα knockdown accelerated wound healing compared to untreated controls. Together, these results serve as proof-of-concept that RNA interference therapy using LNPs can reduce the severity and duration of chronic diabetic wounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.